New Growth Opportunities lie in the Asia-Pacific Active Implantable Medical Devices Market, 2023

Active-Implantable-Medical-Devices-MarketThe global active implantable medical devices market is likely to grow from $17.0 billion in 2016 to $28.9 billion by 2023. Technological advancements, increasing prevalence of cardiovascular diseases, rising healthcare expenditures and increasing research and development activities have been driving the growth of the global active implantable medical devices market. The market is further expected to gain revenue due to increasing geriatric population and incidence of neurological disorders. Development of subcutaneous implantable cardioverter defibrillators along with the increasing demand from developing nations is expected to create ample growth opportunities in the global active implantable medical devices market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/active-implantable-medical-devices-market/report-sample

As per the findings of research, implantable cardioverter defibrillators held the largest share in the global active implantable medical devices market in 2016, primarily due to the development of technologically advanced devices and increasing prevalence of cardiovascular diseases. The neurostimulators market is expected to witness the highest growth during the forecast period. This growth of neurostimulators is attributed to the increasing incidence of neurological disorders and increasing demand from emerging economies. Among different type of implantable cardioverter defibrillators, transevenous implantable cardioverter defibrillators held larger share in the global active implantable medical devices market in 2016, and it is also expected to witness higher growth during the forecast period. Increasing research and development activities and rising compliance for technological innovations and data driven customizations are driving the growth of the global transvenous implantable cardioverter market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/active-implantable-medical-devices-market

Active Implantable Medical Devices Market

Key companies in the active implantable medical devices market are acquiring other companies to strengthen their position in the global market. In January 2017, Abbott completed the acquisition of St. Jude Medical, Inc., including its atrial fibrillation, structural heart and heart failure business as well as neuromodulation business. Similarly, in January 2015, Medtronic plc completed the acquisition of Covidien plc. Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc. The acquisition strengthened position of the company in the global market with a large number of product offerings.

Some of the other key players in the market include Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC, William Demant Holding A/S, Nurotron Biotechnology Co. Ltd., Sonova Holding AG, and MED-EL.

Advertisements

Life Science Instrumentation Market – Global Industry Analysis, Size, Growth and Opportunities

ESA / ESTEC Laboratoria

The global life science instrumentation market is growing due to the technological advancements, increase in funding for life science research, and increasing food safety concerns. Moreover, the increasing research and development activities in pharmaceuticals and biotechnology industries are supporting the growth of the global market. Among the various technologies, next-generation sequencing segment would witness the fastest growth during the forecast period. Development of advanced sequencing platforms, increasing application areas of next-generation sequencing would have high positive impact on the growth of the life science instrumentation market for next generation sequencing. Pharmaceuticals and biotechnology companies were the largest end user of life science instrumentation market in 2015.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/life-science-instrumentation-market/report-sample

The increasing demand for analytical instruments, growing research proteomics research activities, and high growth in emerging economies offer ample growth opportunities in life science instrumentation market. Major analytical instrument manufacturers are focusing for the development of miniaturized instruments, which is the key trend witnessed in the global market. Increasing compliance for hyphenated technologies and increasing collaborations between analytical instrument manufacturers and academic and research institutes are other trends witnessed in the global life science instrumentation market. However, dearth of skilled professionals and high cost of analytical instruments would hinder the growth of the global market to some extent.

Explore more or request TOC on Life Science Instrumentation Market” at: https://www.psmarketresearch.com/market-analysis/life-science-instrumentation-market

The key players operating in the global life science instrumentation market are Danaher Corporation, Agilent Technologies, Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Becton, Dickinson and Company, Bruker Corporation, Bio-Rad Laboratories, Inc. and Waters Corporation.

Graft Versus Host Disease Treatment Market – Global Industry Analysis, Growth, 2023

Graft Versus Host Disease Treatment Market

The global graft versus host disease (GVHD) treatment market is expected to witness considerable growth due to increasing number of hematopoietic stem cell transplantations (HSCTs), advancement in technologies, and increasing collaboration among the pharmaceutical companies. The regulatory bodies are supporting the graft versus host disease market by providing designations and grants for speeding up the drug development process. Currently, there are more than 15 targets, which are being used for the treatment of GVHD including T lymphocytes, OX40, Bruton’s tyrosine kinase, Toll-like receptors, tumor necrosis factor alpha, neutrophil elastase, and several B and T lymphocytes. Some of the companies use their own technologies for the development of drugs for graft versus host disease such as Bellicum Pharmaceuticals, Inc. and Targazyme, Inc.  Bellicum Pharmaceuticals, Inc. is using CaspaCIDe technology and Targazyme, Inc. is using Fucosylation technology.

Explore Report at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market

The pipeline of GVHD is very rich with more than 60 drugs. Top pharmaceutical companies such as Dr. Falk Pharma GmbH and Mallinckrodt plc are expected to launch their products in coming years, as the products are in Phase III stage of development. The therapeutics involved in the treatment of GVHD comprise different molecule types including antibody drug conjugate, antibodies, cell therapy, monoclonal antibodies and recombinant proteins.

GVHD is a common condition associated with allogeneic hematopoietic stem cell transplantation. It occurs when the donor cells are rejected and attack the recipient’s cells as foreign cell. It can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). The most common organs affected by aGVHD and cGVHD include skin, gastrointestinal tract, liver, oral mucosa and eyes. The affected people were recognized on the basis of number of allogeneic cell transplantation.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market/report-sample

Some of the key players operating in the global market are Dr. Falk Pharma GmbH, Mallinckrodt Pharmaceuticals, Apceth GmbH & Co. KG, Targazyme Inc., Bellicum Pharmaceuticals, Inc., Cellect Biotechnology Ltd., Sanofi, Novartis AG, Gilead Sciences, Inc., AbbVie Inc., and Takeda Pharmaceutical Company Ltd.

Natural Killer Cell Therapeutics Market – Pipeline Analysis, Size and Growth, 2023

The global natural killer (NK) cell therapeutics market is expected to witness considerable growth due to increasing awareness regarding immunotherapy, advancement in technologies, high demand for safe and effective medication, reduction of side effects, high prevalence of chronic diseases such as cancer and cardiovascular diseases, and increasing incidences of infectious diseases. The regulatory bodies are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Some drug candidates, such as Mogamulizumab, Lorvotuzumab Mertansine, AFM 13, FPA144, and NKTT-120, got orphan drug designation and fast track designation for NK cell therapeutics.

Explore Report at: https://www.psmarketresearch.com/market-analysis/nk-cell-therapeutics-market

The pipeline of NK cell therapeutics market is rich with more than 30 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NK cells. Kyowa Hakko Kirin Co., Ltd. has Mogamulizumab drug in its Phase III clinical trial for NK cells therapeutics. Increasing use of combination therapy of NK cells is also a potential growth driver for the growth of the global market. Use of NK cells with Chimeric Antigen Receptor (CAR) T-Cell therapy helps to enhance the efficacy of the medication.

NK cells are granular lymphocytes that provide innate immunity and first line of defense against viral infections and cancer. Natural killer cells are made up of 5–15% circulating lymphocytes. It is found in peripheral tissues including liver, peritoneal cavity, and placenta. NK cell are activated by interleukins that is capable of extravasations and infiltration into tissues.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/nk-cell-therapeutics-market/report-sample

Some of the key players operating in the global NK cells market are Chipscreen Biosciences, Ltd. Affimed N.V., Altor BioScience Corporation, Innate Pharma S.A., Takeda Pharmaceutical Company Limited, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, and NKT Therapeutics, Inc.

ADCs Therapeutics Market – Pipeline Analysis, Share, Growth and Forecast to 2023

The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.

Explore Report at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market

The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.

ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/report-sample

Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.

Chronic Pain Treatment Market – Pipeline Analysis, Share and Growth, 2023

Human Joints ConceptThe global chronic pain treatment market is expected to witness considerable growth due to current unmet medical need of chronic pain, technological advancement in pain therapeutic and diagnostic test, and increasing number of chronic diseases such as cancer, arthritis, and diabetes mellitus. In addition, increasing geriatric population and increasing disposable income are supporting the growth of the global chronic pain market. The pharmaceutical companies are actively involved in the research and development of drugs for chronic pain. Camurus is developing CAM2038, long-acting subcutaneous buprenorphine injections for the treatment of opioid dependence and pain.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market/report-sample

Chronic pain is defined as the pain that persists for more than 3 months or longer. It adversely affects patient’s quality of life that may limit a person’s movements, which can interfere with daily activities. This difficulty in carrying out work related or other activities can lead to disability and despair. Chronic pain persists and sends pain signals to the nervous system for weeks, months or even years. It also affects the peripheral and central nervous system called neuropathy that result from damage to or pathological changes of the peripheral or central nervous system. The actual cause of chronic pain is unknown. Some people feel chronic pain without having any past injury or evidence of body damage.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market

Some of the key players operating in the global chronic pain market are Pfizer, Inc., Cara Therapeutics, Inc., Endo Pharmaceuticals Inc., Teikoku Pharma USA, Inc., Allergan plc, Purdue Pharma L.P., Mallinckrodt plc, AstraZencea plc, Jazz Pharmaceuticals plc, and Nektar Therapeutics.

Biosurgery Market – Global Industry Analysis, Size, Trends, 2023

Biosurgery Market

The global biosurgery market is witnessing considerable growth due to increasing geriatric population, increasing healthcare expenditure and growing sports related injuries. Moreover, growing prevalence of chronic diseases including cancer, cardiovascular disease, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases is supporting the growth of the market. Based on product type, the surgical sealants segment is expected to grow at the fastest rate during the forecast period. The increasing adoption of biosurgery products across the globe, owing to its ease of use, and its efficacy in blood loss management is driving the growth of this segment.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/biosurgery-market/report-sample

Cancer is a serious health concern across the globe. The increasing prevalence of cancer is driving the growth of the biosurgery market globally. According to the International Agency for Research on Cancer (IARC), a specialized cancer agency of WHO that promotes cancer research, as many as 12.7 million new patients were detected with cancer in 2008 globally and the number is expected to reach 21.4 million by 2030. Further, a total of 8.2 million deaths took place globally due to cancer in 2012, of which 1.6 million deaths were due to lung cancer, while 745,000 deaths were due to liver cancer, and 400,000 deaths were a result of oesophageal cancer.

Geriatric pool has weakened body functions, impaired blood circulation and are more susceptible to chronic diseases. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with high rate. In 2013, the global percentage of people aged 60 or above was 11.7% and it is expected to reach 21.1% by the end of 2050. Further, the number of people aged 60 years and above is expected to reach approximately 437 million in China, 324 million in India, 107 million in the U.S. and 58 million in Brazil by 2050.

Explore Report at: https://www.psmarketresearch.com/market-analysis/biosurgery-market

The key players operating in the global biosurgery market are Baxter International Inc., C.R. Bard, Inc., Medtronic, Inc., Johnson & Johnson, Sanofi Group, B. Braun Melsungen AG, Cryolife, Stryker Corporation and Hemostasis, LLC.

Orthopedic Devices Market – Global Industry Analysis, Size and Demand, 2023

Orthopedic Devices Market

Orthopedics is a branch of medicine that is concerned with the prevention of disorders, deformities or injuries of the skeleton and associated structures such as tendons and ligaments. Orthopedic devices are used to implant and restore the skeletal structure and joint movement after the disorders such as fractures, abnormal growth of bones, soft tissue damage and other deformities. Orthopedic devices had been used effectively in reducing pain, restoring mobility and improving quality of life of the consumers across the globe. Before implanting an orthopedic device into patient’s body, doctors check x-ray and scan report of patient to diagnose the disorders. Doctors implant orthopedic devices that are well suited for the patient’s body, as most of the devices have to remain in the body for the remaining life of patient.

For more information visit: https://www.psmarketresearch.com/market-analysis/orthopedic-devices-market

In orthopedic devices, generally metal alloys are used due to their properties such as rigidity, fracture toughness, corrosion resistance, long fatigue life, stiffness, and biocompatibility. Whereas, polymers are used as articulating surfaces of joint replacements and as a cementing material between implant surfaces and bone. Polyether ether ketone (PEEK) implants are generally used for spinal implants as it has advantages such as high mechanical strength.

The various devise types available in the global orthopedic devices market are joint reconstruction, orthobiologics, trauma fixation devices, spinal devices, orthopedic accessories, orthopedic braces, and arthroscopic devices.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/orthopedic-devices-market/report-sample

North America dominates the global orthopedic devices market, attributed to high per capita expenditure on the healthcare services in the region. Asia-Pacific is the fastest growing market for orthopedic devices owing to the large population, increasing incidence of lifestyle diseases and development of modern healthcare service industry in the region.

Some of the major companies operating in the orthopedic devices market are Zimmer Holdings Inc., Medtronic Inc., Wright Medical Technology Inc., Orthofix Holdings Inc., NuVasive Inc., TriMed Inc., Stryker Corporation, Smith & Nephew PLC, Small Bone Innovations Inc., Solana Surgical LLC, DePuy Synthes Inc. Integra LifeSciences, Aesculap, Inc., and ArthroCare Corporation.

Pre-Clinical Imaging (In-vivo) Market – Global Industry Analysis, Size and Future Scope

Pre-Clinical Imaging MarketThe global pre-clinical imaging (in-vivo) market is growing significantly due to development of high resolution and sensitive imaging devices with various applications in the industry. Massive unexplored market in pre-clinical imaging (in-vivo) industry of developing economies are creating ample opportunities for the pre clinical imaging market to grow at a considerable rate in the coming years. Further, technological advancement in pre-clinical imaging will support the growth of the global pre-clinical imaging (in-vivo) market in the coming years.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/pre-clinical-imaging-market/report-sample

Pre-clinical (in-vivo) imaging is bridging a gap between the vivo clinical research and vitro exploratory. It is increasingly being deployed across the drug development process, specifically in oncology therapeutic area. The advanced research and development facilities and new product developments of the companies are supporting the growth of pre-clinical imaging (in-vivo) industry. Moreover, integration of pre-clinical MRI systems with other imaging modalities is also expected to propel the growth of the global pre-clinical imaging market in coming years.

On the basis of type of modalities of pre-clinical imaging (in-vivo), the market can be categorized as optical imaging systems, pre-clinical nuclear imaging systems, micro-magnetic resonance imaging (MRI), micro-ultrasound, micro-CT, pre-clinical photoacoustic imaging system, pre-clinical magnetic particle imaging system and others. The optical imaging system lead the pre-clinical imaging (in-vivo) market, by type of modalities category; whereas, the pre-clinical nuclear imaging system segment is expected to grow with the fastest rate in the coming years due to rising adoption of pre-clinical imaging and development of technologically hybrid nuclear imaging systems.

Explore Report at: https://www.psmarketresearch.com/market-analysis/pre-clinical-imaging-market

Some of the companies operating in the pre-clinical imaging (in-vivo) market are Perkinelmer Inc., Mr Solutions Ltd., Mediso Ltd., Bruker Corporation, Trifoil Imaging, Fujifilm Visualsonics Inc., Biospace Lab S.A., Milabs B.V., Li-Cor Biosciences, Thermo Fisher Scientific, Agilent Technologies and Aspect Imaging.

 

Ophthalmology Devices Market Analysis, Drivers, Trends, Challenges and Demand, 2023

Ophthalmology Devices Market

The global ophthalmology devices market is growing significantly due to increasing prevalence of eye diseases, and technological advancements in ophthalmic devices. Shortages of ophthalmology devices providers in emerging economies and increasing age-related eye diseases are creating ample opportunities for the ophthalmology devices market to grow at a considerable rate in the coming years. The advanced research and development facilities and new product developments by the companies are propelling the demand for cost effective ophthalmic devices.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ophthalmology-devices-market

The ophthalmology devices market is segmented on the basis of therapeutic applications, end-users, and products type. Based on therapeutic applications, the ophthalmology devices market can be categorized as diabetes retinopathy, cataract, macular degeneration, glaucoma, and others. Cataract leads the ophthalmology devices market due to high prevalence of cataract worldwide. Based on end-user, the ophthalmology devices market can be segmented as academic institutes and research laboratories, hospitals and others.

On the basis of products type, the ophthalmology devices market can be categorized as vision care devices, diagnostic devices, and surgical devices. The diagnostic devices segment includes optical coherence tomography (OCT) scanners, ophthalmic ultrasound imaging systems, fundus camera, retinoscopes and ophthalmoscopes, corneal topographers, visual field analyzers, tonometers, slit lamps, specular microscope, wavefront aberrometers, autorefractors, biometer, optotype projectors, and others. The surgical devices segment includes vitreoretinal surgery devices, cataract surgery devices, glaucoma surgery devices, and refractive surgery devices. Whereas, vision care devices segment includes spectacle lenses and contact lenses. Vision care devices segment is expected to grow with the fastest rate in the coming years.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ophthalmology-devices-market/report-sample

Some of the major players operating in the global ophthalmology devices market are Alcon Inc., Bausch & Lomb Inc., Abbott Medical Optics, Topcon Corporation, Carl Zeiss Meditec AG, Haag Streit, Johnson & Johnson, Nidek Co. Ltd., STAAR Surgicals, Hoya Corporation, Essilor International S.A., and Zeimer Ophthalmic Systems AG among others.